# All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

> **NCT04433169** · PHASE2 · UNKNOWN · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 30 (estimated)

## Conditions studied

- Adenoid Cystic Carcinoma of the Head and Neck

## Interventions

- **DRUG:** All-trans Retinoic Acid
- **DRUG:** VEGFR inhibitor
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04433169
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-03
- **Primary completion:** 2022-12
- **Final completion:** 2023-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433169, "All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04433169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*